Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

241 results about "Stable Isotope Labeling" patented technology

Isotopic labeling (or isotopic labelling) is a technique used to track the passage of an isotope ... Stable isotope labeling involves the use of non-radioactive isotopes that can act as a tracers used to model several chemical and biochemical systems.

Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity

The methods described herein enable the evaluation of compounds on subjects to assess their therapeutic efficacy or toxic effects. The target of analysis is the underlying biochemical process or processes (i.e., metabolic process) thought to be involved in disease pathogenesis. Molecular flux rates within the one or more biochemical processes serve as biomarkers and are quantitated and compared with the molecular flux rates (i.e., biomarker) from control subjects (i.e., subjects not exposed to the compounds). Any change in the biomarker in the subject relative to the biomarker in the control subject provides the necessary information to evaluate therapeutic efficacy of an administered drug or a toxic effect and to develop the compound further if desired. In one aspect of the invention, stable isotope-labeled substrate molecules are administered to a subject and the label is incorporated into targeted molecules in a manner that reveals molecular flux rates through one or more metabolic pathways of interest. By this method, a comparison between subjects and control subjects reveals the effects of the chemical entity or entities on the biomarkers. This, in turn, allows for the identification of potential therapeutic uses or toxicities of the compound. Combinations of compounds can also be systematically evaluated for complementary, synergistic, or antagonistic actions on the metabolic pathways of interest, using the methods of the present invention as a strategy for identifying and confirming novel therapeutic or toxic combinations of compounds.
Owner:RGT UNIV OF CALIFORNIA

Methods for measuring cellular proliferation and destruction rates in vitro and in vivo

The present invention relates to methods for measuring the proliferation and destruction rates of cells by measuring deoxyribonucleic acid (DNA) synthesis and / or destruction. In particular, the methods utilize non-radioactive stable isotope labels to endogenously label DNA synthesized through the de novo nucleotide synthesis pathway in a cell. The amount of label incorporated in the DNA is measured as an indication of cellular proliferation. The decay of labeled DNA over time is measured as an indication of cellular destruction. Such methods do not involve radioactivity or potentially toxic metabolites, and are suitable for use both in vitro and in vivo. Therefore, the invention is useful for measuring cellular proliferation or cellular destruction rates in humans for the diagnosis, prevention, or management of a variety of disease conditions in which cellular proliferation or cellular destruction is involved. The invention also provides methods for measuring proliferation or destruction of T cells in a subject infected with human immunodeficiency virus (HIV) and methods of screening an agent for a capacity to induce or inhibit cellular proliferation or destruction. In addition, the invention provides methods for measuring cellular proliferation in a proliferating population which utilize both radioactive isotope labels and stable isotopes to endogenously label DNA through the de novo nucleotide synthesis pathway.
Owner:RGT UNIV OF CALIFORNIA

Phospholipid classification detection and quantification method based on stable isotope labeling

The present invention discloses a phospholipid classification detection and quantification method based on stable isotope labeling, and belongs to the technical field of phospholipid quantification detection methods. According to the method, mainly trimethylsilyl diazomethane is used to respectively generate diazomethane and deuterium-labeled diazomethane in a methyl tert-butyl ether/methanol/1N hydrochloric acid solution system and a methyl tert-butyl ether/deuteromethanol/1N deuterium chloride solution system in an in-situ manner so as to further respectively carry out methyl esterification on the phosphoric acid group or carboxylic acid group in the phospholipid molecule to generate the light isotope labeled-phospholipid methyl esterification derivative and the heavy isotope labeled-phospholipid methyl esterification derivative, wherein the light isotope labeled-phospholipid methyl esterification derivative and the heavy isotope labeled-phospholipid methyl esterification derivative have the same physical and chemical properties and different molecular weights; and the relative intensity of the light isotope labeled-mass spectrum peak signal and the heavy isotope labeled-mass spectrum peak signal are compared to associate with the phospholipid molecule amount in the sample so as to achieve the relative quantification on the phospholipid. The method of the present invention has characteristics of enhanced sensitivity and completion within a shor time.
Owner:INSITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products